Bacteriophage having bacteriolytic activity against xanthomonas bacteria

A novel bacteriophage with a unique genomic sequence is used to create a bacteriolytic agent that specifically targets Xanthomonas bacteria, addressing the limitations of existing disease control methods by providing effective and environmentally safe plant disease control.

WO2024248029A1PCT designated stage expired Publication Date: 2024-12-05KANEKA CORP +2
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
PCT/JP2024/019669
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-31
Filing Date
2024-05-29
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Current methods for controlling plant diseases caused by Xanthomonas bacteria, such as copper agents and antibiotics, often result in drug efficacy issues, damage, and disruption of bacterial flora balance, necessitating the development of a more specific and safe alternative.

Method used

Isolation and use of a novel bacteriophage with a unique genomic DNA sequence that exhibits lytic activity against Xanthomonas bacteria, forming the basis of a bacteriolytic agent and plant disease control composition, which is highly specific and harmless to humans and plants.

Benefits of technology

The bacteriolytic agent effectively lysing target bacteria, preventing and suppressing plant diseases while maintaining environmental safety and avoiding chemical damage, offering a sustainable pesticide solution.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure JP2024019669_05122024_PF_FP_ABST
    Figure JP2024019669_05122024_PF_FP_ABST
Patent Text Reader

Abstract

To control plant diseases caused by Xanthomonas bacteria, a novel bacteriophage exhibiting bacteriolytic activity specifically against Xanthomonas bacteria was isolated, and a plant disease control composition containing the bacteriophage as an active ingredient was developed and provided. Provided are a bacteriolytic agent comprising a bacteriophage that has a novel genomic DNA sequence and exhibits bacteriolytic activity specifically against Xanthomonas bacteria, and a plant disease control composition containing the bacteriophage as an active ingredient.
Need to check novelty before this filing date? Find Prior Art

Description

Xanthomonas lytic bacteriophage

[0001] The present invention relates to a lytic agent comprising a bacteriophage, a plant disease control composition containing the same, and a plant disease control method.

[0002] Bacteriophages (often abbreviated as "phages" herein) are a general term for viruses that infect only bacteria. Many phages, also known as lytic phages, specifically adsorb to a target bacterium (host), inject their own DNA, and self-amplify using the bacterial translation machinery. They then lyse the bacterium, allowing the amplified phages to spread and repeatedly infect new target bacteria (Non-Patent Document 1).

[0003] Many Xanthomonas bacteria are known to cause diseases of various crops and other plants, and copper compounds and antibiotics have been used as common control methods. However, due to many problems, such as inefficacy, phytotoxicity, and the potential for disruption of the bacterial flora balance, phage-based methods have recently attracted attention as a new control method (Non-Patent Document 2).

[0004] Phages that exhibit lytic activity against Xanthomonas bacteria have been reported, for example, in Patent Documents 1 to 3 and Non-Patent Document 2. However, because the host range of phages is extremely narrow, it remains important to search for new phages and discover phages with higher lytic activity.

[0005] JP 2016-32435 A JP 2021-102635 A International Publication No. 2017 / 113029

[0006] Sharma S. et al., Folia Microbiol., 2017, 62:17-55Nakayinga R. et al., BMC Microbiology, 2021, 21:291

[0007] To solve the above problems, the present inventors focused on bacteriophages. Unlike conventional copper agents and antibiotics, phages are viruses and natural products, and no reports of phytotoxicity have been reported to date. Furthermore, because phages have high host specificity, they target only specific genera and species of bacteria, resulting in extremely limited impact on the balance of the microflora. They are also harmless to humans and other animals, as well as plants, and are highly safe. Therefore, in order to reduce damage to agricultural crops caused by plant diseases caused by Xanthomonas bacteria, a novel phage exhibiting lytic activity against Xanthomonas bacteria was isolated. Another objective of the present invention is to provide a composition containing the phage as an active ingredient and to use the composition in disease control, pathogenic bacterial detection, and other applications.

[0008] The present inventors isolated novel phages from natural wastewater and soil using a technique for detecting lytic plaques formed on soft agar media cultured with Xanthomonas bacteria, and analyzed their genome sequences. As a result, it was revealed that the phages possess novel genome DNA sequences with no known related genome sequences. The present invention was completed based on the results of the above research and development. Specifically, the present invention provides the following:

[0009] [1] A lytic agent comprising a bacteriophage having a genomic DNA sequence consisting of the nucleotide sequence shown in any one of SEQ ID NOs: 1 to 3. [2] The lytic agent according to [1], which exhibits lytic activity against bacteria of the genus Xanthomonas. [A-1] A lytic agent comprising a bacteriophage having a genomic DNA sequence comprising any one of the nucleotide sequences shown in (1a) to (1c) below: (1a) the nucleotide sequence shown in SEQ ID NO: 1, (1b) a nucleotide sequence in which one or more nucleotides have been added, deleted, and / or substituted in the nucleotide sequence shown in SEQ ID NO: 1, or (1c) a nucleotide sequence having 95% or more sequence identity to the nucleotide sequence shown in SEQ ID NO: 1. [A-2] The lytic agent according to [A-1], which exhibits lytic activity against bacteria of the genus Xanthomonas. [A-3] The bacteriolytic agent according to [A-2], wherein the Xanthomonas bacterium is at least one bacterium selected from the group consisting of Xanthomonas arboricola, Xanthomonas campestris, and Xanthomonas citri. [B-1] A bacteriolytic agent comprising a bacteriophage having a genomic DNA sequence of 40,000 bases or less in total length, comprising any one of the following nucleotide sequences (2a) to (2c): (2a) the nucleotide sequence shown in SEQ ID NO: 2, (2b) the nucleotide sequence shown in SEQ ID NO: 2 in which one or more nucleotides have been added, deleted, and / or substituted, or (2c) a nucleotide sequence having 90% or more sequence identity to the nucleotide sequence shown in SEQ ID NO: 2. [B-2] The bacteriolytic agent according to [B-1], which exhibits lytic activity against Xanthomonas bacteria. [B-3] The bacteriolytic agent according to [B-2], wherein the Xanthomonas bacterium is Xanthomonas arboricola and / or Xanthomonas campestris. [C-1] A bacteriolytic agent comprising a bacteriophage having a genomic DNA sequence containing any one of the following nucleotide sequences (3a) to (3c): (3a) the nucleotide sequence shown in SEQ ID NO: 3, (3b) a nucleotide sequence in which one or more nucleotides have been added, deleted, and / or substituted in the nucleotide sequence shown in SEQ ID NO: 3, or (3c) a nucleotide sequence having 90% or more sequence identity to the nucleotide sequence shown in SEQ ID NO: 3.[C-2] The lytic agent according to [C-1], which exhibits lytic activity against bacteria of the genus Xanthomonas. [C-3] The lytic agent according to [C-2], wherein the Xanthomonas bacterium is Xanthomonas arboricola and / or Xanthomonas campestris. [3] A composition comprising, as an active ingredient, the lytic agent according to any one of [1] or [2], or [A-1] to [C-3]. [4] A plant disease control composition comprising the composition according to [3]. [5] The plant disease control composition according to [4], wherein the plant disease is a plant disease caused by bacteria of the genus Xanthomonas. [6] The plant disease control composition according to [4] or [5], which comprises another bacteriophage exhibiting lytic activity against bacteria of the genus Xanthomonas. [7] A plant disease control method comprising a contacting step of contacting a target plant with the plant disease control composition described in any one of [4] to [6]. [8] A method for identifying a bacterium of the genus Xanthomonas, comprising a culturing step of culturing a test bacterium isolated from plant tissue infected with a plant disease to obtain a culture, a mixing step of mixing the culture with the lytic agent described in [2] to obtain a mixture, a mixture culturing step of culturing the mixture under predetermined conditions, and a determination step of determining that the test bacterium is a bacterium of the genus Xanthomonas if the test bacterium is lysed after the mixture culturing step. [9] The method described in [8], wherein in the mixture culturing step, the mixture further comprises a soft agar-containing liquid medium, and the mixture is cultured on a solid medium.

[10] The method described in [8], wherein in the culture step, the culture comprises a soft agar-containing liquid medium, and the culture is cultured on a solid medium.

[11] The method described in any one of [8] to

[10] , further comprising an isolation step of isolating the test bacterium from plant tissue infected with a plant disease before the culturing step. This specification includes the disclosure of Japanese Patent Application No. 2023-089380, from which the present application claims priority.

[0010] The bacteriolytic agent of the present invention and a composition containing it as an active ingredient can lyse specific target bacteria.

[0011] The plant disease control composition of the present invention can prevent and suppress diseases caused by specific target bacteria.

[0012] 1 shows the lytic activity of the first bacteriophage obtained in Example 1. FIG. 1A is a diagram showing Xanthomonas bacteria and control Pseudomonas fluorescens cultured on an agar plate, after which the first phage purified solution was dropped onto the center of the plate and statically cultured. FIG. 1B is a diagram showing the plate corresponding to FIG. 1A, showing the bacteria shown in Table 2 spread on each plate. FIG. 1A is a diagram showing the lytic activity of the first bacteriophage obtained in Example 1. FIG. 1A is a diagram showing the Xanthomonas bacteria and control Pseudomonas fluorescens cultured on an agar plate, after which the first phage purified solution was dropped onto the center of the plate and statically cultured. FIG. 1B is a diagram showing the plate corresponding to FIG. 1A, showing the bacteria shown in Table 2 spread on each plate. FIG. 1B is a diagram showing the lytic activity of the second bacteriophage obtained in Example 2. FIG. 1A is a diagram showing Xanthomonas bacteria and control Pseudomonas fluorescens cultured on an agar plate, after which the second phage purified solution was dropped onto the center of the plate and statically cultured. FIG. 1B is a diagram showing the plate corresponding to FIG. 1A, showing the bacteria shown in Table 4 spread on each plate. FIG. 1C is a diagram showing the lytic activity of the second bacteriophage obtained in Example 2. FIG. 1A is a diagram showing the Xanthomonas bacteria and control Pseudomonas fluorescens cultured on an agar plate, after which the second phage purified solution was dropped onto the center of the plate and statically cultured. FIG. 1B is a diagram showing the plate corresponding to FIG. 1A, showing the bacteria shown in Table 4 spread on each plate. FIG. 1C is a diagram showing the lytic activity of the third bacteriophage obtained in Example 3. FIG. 1A is a diagram showing the Xanthomonas bacteria and control Pseudomonas fluorescens cultured on an agar plate, after which the third phage purified solution was dropped onto the center of the plate and statically cultured. B is a plate diagram corresponding to A, showing the bacteria shown in Table 5 spread on each plate. This is a diagram showing the lytic activity of the combination of the first bacteriophage and other bacteriophages tested in Example 4. A is a diagram showing Xanthomonas bacteria spread on an agar plate, which was then cultured, and the purified phage solution was added dropwise to the plate and allowed to stand.6A and 6B are plate diagrams corresponding to those in A, showing the types of phages contained in the phage purification solution dropped onto each plate. In Figures 6A and 6B, the left two columns (1, 2, 5, 6, 9, and 10) show plates on which bacteria with an ID of MAFF No. 673005 were spread, and the right two columns (3, 4, 7, 8, 11, and 12) show plates on which bacteria with an ID of MAFF No. 301352 were spread. In Figure B, a represents a first phage having the genomic DNA sequence of SEQ ID NO: 1; b represents a phage having the genomic DNA sequence of SEQ ID NO: 4; c represents a phage having the genomic DNA sequence of SEQ ID NO: 5; d represents a phage having the genomic DNA sequence of SEQ ID NO: 6; e represents a phage having the genomic DNA sequence of SEQ ID NO: 7; f represents a second phage having the genomic DNA sequence of SEQ ID NO: 2; g represents a third phage having the genomic DNA sequence of SEQ ID NO: 3; and h represents a phage having the genomic DNA sequence of SEQ ID NO: 8. In the figure, a " / " indicates that the phages before and after it were used in combination. For example, "a / f" indicates that the first phage and the second phage are used in combination. These figures show the lytic activity of combinations of the second bacteriophage and other bacteriophages tested in Example 5. (A) shows a diagram of Xanthomonas bacteria cultured on an agar plate, followed by dropping a purified phage solution onto the plate and allowing it to stand. (B) shows a diagram of a plate corresponding to (A), indicating the type of phage contained in the purified phage solution dropped onto each plate. In Figures 7A and 7B, the left two columns (1, 2, 5, 6, 9, and 10) show plates on which bacteria with an ID of MAFF No. 673005 were cultured, and the right two columns (3, 4, 7, 8, 11, and 12) show plates on which bacteria with an ID of MAFF No. 301352 were cultured. In Figure B, a represents the second phage having the genomic DNA sequence of SEQ ID NO: 2, b represents the phage having the genomic DNA sequence of SEQ ID NO: 4, c represents the phage having the genomic DNA sequence of SEQ ID NO: 5, d represents the phage having the genomic DNA sequence of SEQ ID NO: 6, e represents the phage having the genomic DNA sequence of SEQ ID NO: 7, f represents the first phage having the genomic DNA sequence of SEQ ID NO: 1, g represents the third phage having the genomic DNA sequence of SEQ ID NO: 3, and h represents the phage having the genomic DNA sequence of SEQ ID NO: 8.In the figure, a " / " indicates that the phages before and after it were used in combination. For example, "a / f" indicates that the second phage was used in combination with the first phage. This figure shows the lytic activity of the combinations of the second bacteriophage and other bacteriophages tested in Example 6. Panel A shows a diagram of Xanthomonas bacteria cultured on an agar plate, followed by a drop of purified phage solution onto the plate and static incubation. Panel B shows a plate corresponding to panel A, indicating the type of phage contained in the purified phage solution dropped onto each plate. In Figures 8A and 8B, the two leftmost columns (1, 2, 5, 6, 9, and 10) show plates on which bacteria with an ID of MAFF No. 673005 were cultured, the third column from the left (3, 7, and 11) shows plates on which bacteria with an ID of MAFF No. 301257 were cultured, and the rightmost columns (4, 8, and 12) show plates on which bacteria with an ID of MAFF No. 106765 were cultured. In Figure B, a represents the third phage having the genomic DNA sequence of SEQ ID NO:3, b represents the phage having the genomic DNA sequence of SEQ ID NO:4, c represents the phage having the genomic DNA sequence of SEQ ID NO:5, d represents the phage having the genomic DNA sequence of SEQ ID NO:6, e represents the phage having the genomic DNA sequence of SEQ ID NO:7, f represents the first phage having the genomic DNA sequence of SEQ ID NO:1, g represents the second phage having the genomic DNA sequence of SEQ ID NO:2, and h represents the phage having the genomic DNA sequence of SEQ ID NO:8. In the figure, " / " indicates that the phages before and after it are used in combination. For example, "a / f" indicates that the third phage and the first phage are used in combination. This is a graph showing the results of a disease control efficacy test against bacterial spot of tomato tested in Example 7. The average disease incidence is shown as a relative value to the untreated group. This is a graph showing the results of a disease control efficacy test against black rot of broccoli tested in Example 8. The average disease incidence is shown as a relative value to the untreated group. The numbers shown in each bar graph indicate the type of phage used.In the figure, a represents a third phage having the genomic DNA sequence of SEQ ID NO: 3, b represents a phage having the genomic DNA sequence of SEQ ID NO: 9, c represents a phage having the genomic DNA sequence of SEQ ID NO: 8, d represents a phage having the genomic DNA sequence of SEQ ID NO: 10, e represents a phage having the genomic DNA sequence of SEQ ID NO: 5, f represents a phage having the genomic DNA sequence of SEQ ID NO: 6, g represents a phage having the genomic DNA sequence of SEQ ID NO: 7, and h represents a phage having the genomic DNA sequence of SEQ ID NO: 11. In the figure, " / " indicates that the phages before and after it are used in combination. For example, "a / b" indicates that the third phage is used in combination with a phage having the genomic DNA sequence of SEQ ID NO: 9.

[0013] 1. Lytic Agent 1-1. Overview A first aspect of the present invention is a lytic agent. The lytic agent of the present invention comprises a bacteriophage having a genome sequence including a specific base sequence. The lytic agent of the present invention exhibits specific lytic activity against target bacteria that may be pathogenic bacteria causing plant diseases.

[0014] 1-2. Definitions Terms used in this specification are defined below.

[0015] As used herein, the term "lytic agent" refers to an agent consisting of a bacteriophage that has lytic activity against target bacteria.

[0016] "Bacteria" is one of the major lineages of organisms that divides the entire living kingdom into three parts, along with archaea and eukaryotes. Bacteria are composed of cells without a nucleus and can self-replicate if they have a source of nutrition. Based on the International Code of Bacteriological Nomenclature, bacteria are named by family, genus, and species.

[0017] As used herein, "target bacteria" refers to host bacteria that can be targeted by the phages that constitute the lytic agent of the present invention, or the phages contained in the composition and plant disease control composition of the present invention. For example, it is a bacterium that has a membrane surface receptor on the outer cell membrane that is recognized by the phage. The "membrane surface receptor" is the site where, for example, the tail and tail fibers of the phage bind, and is composed of proteins, lipopolysaccharides, pili, etc. present in the outer layer of the bacterial outer membrane. Specific examples of target bacteria in this specification include bacteria of the genus Xanthomonas.

[0018] "Xanthomonas bacteria" are bacteria belonging to the genus Xanthomonas. Xanthomonas bacteria generally produce a yellow pigment called xanthomonadin, and many of them are known to be plant pathogens. Classifications below species include subtypes and pathovar, which are indicated by adding subsp. or pv. after the bacterial name, respectively. The smallest unit of classification is the strain, which refers to a group of cells that are considered to be genetically uniform. Table 1 below shows representative Xanthomonas bacteria, their host plants, and the plant diseases they cause.

[0019]

[0020] Among Xanthomonas bacteria, Xanthomonas arboricola, Xanthomonas citri, and Xanthomonas campestris are particularly preferred as target bacteria of the present invention, but are not limited thereto. Specific examples of Xanthomonas arboricola include Xanthomonas arboricola pv. pruni, which has the pathotype pruni, and Xanthomonas arboricola pv. juglandis, which has the pathotype juglandis. Specific examples of Xanthomonas citri include Xanthomonas citri subsp. citri. Specific examples of Xanthomonas campestris include Xanthomonas campestris pv. vesicatoria, which has the pathotype vesicatoria, Xanthomonas campestris pv. vitians, which has the pathotype vitians, and Xanthomonas campestris pv. campestris, which has the pathotype campestris.

[0021] "Bacteriophage" (often abbreviated as "phage" herein, as mentioned above) is a general term for viruses that infect bacteria. A typical phage consists of three parts: a head, a tail, and tail fibers. The head is composed of a capsomere, a protein coat, and an icosahedral capsid (viral shell), which contains the phage's genomic DNA within its internal space. The tail has a tubular structure composed of a tail tube protein and a sheath protein covering it. One end of the tail is connected to the head, and the other end is connected to the tail fiber. The tail functions as an introduction tube, injecting the genomic DNA from the head into the host bacterial cell. The tail and tail fibers are composed of several fibrous structures composed of tail fiber proteins. The tail and tail fibers perform host recognition and adsorption functions by recognizing receptors present on the outer membrane surface of the host bacterial cell and adsorbing to the cell surface. Phages have extremely high host specificity, a characteristic based on the function of their tails and tail fibers. Because phages do not infect eukaryotes, drugs using phages are harmless to humans, animals, and plants. Phages are broadly classified into "lytic cycle," "lysogenic cycle," and "lytic / lysogenic cycle" based on their mode of infection. In the lysogenic cycle, phages integrate their own DNA into the bacterial chromosome without lysing the target bacterium, and grow along with the growth of the bacterium. In the lytic cycle, phages self-multiply within the host bacterial cells, then lyse the host bacterium and release large amounts of progeny phages. The phages of the present invention are virulent phages that undergo the lytic cycle.

[0022] As described above, the "tail fiber protein" refers to a protein that constitutes the tail fiber of a phage. The tail fiber protein is known to play an important role in the specificity of the tail and tail fiber in host recognition and adsorption (Nobrega FL et al., Nat. Rev. Microbiol., 2018, 16:760-773).

[0023] The term "tail fiber gene" refers to a gene contained in the genomic DNA of a phage and encoding the tail fiber protein.

[0024] As mentioned above, "tail tube proteins" are proteins that make up the tubular structure of the phage tail. They interact with the tail fibers and, together with the tail fibers, play an important role in the specificity of host recognition and adsorption (Maozhi Hu, et al., 2020, 9:1, 855-867). Known tail tube proteins include tail tube fiber protein A and tail tube protein B. "Tail tube protein A" is a protein that forms a ring at the bottom of the tubular structure of the tail and interacts with the tail fibers. "Tail tube protein B" is a protein that forms the lower end of the tubular structure of the tail and binds to a receptor present on the outer membrane surface of the host bacterium.

[0025] The term "tailtube gene" refers to a gene contained in the phage genomic DNA that encodes the tailtube protein. The term "tailtube protein A gene" refers to the gene encoding tailtube protein A, and the term "tailtube protein B gene" refers to the gene encoding tailtube protein B.

[0026] "Bacteriolysis" refers to the phenomenon of destroying the bacterial cell membrane. As mentioned above, this phenomenon is mainly seen in the infection mode of virulent phages. Bacteria die through lysis. Bacteriolysis begins when the phage specifically adsorbs to the target bacterium and injects its own DNA into the target bacterial cell via its tail. The phage then uses the bacterial translation mechanism to replicate itself and produce a large amount of progeny phages, which then lyse the bacterium and release them into the outside world.

[0027] As used herein, "plant disease" refers to a general term for diseases that occur in plants. Known plant diseases include diseases caused by infectious pathogens such as viruses, bacteria, filamentous fungi, actinomycetes, viroids, phytoplasmas, nematodes, mites, or insects, as well as diseases caused by non-infectious pathogens such as a lack or excess of nutrients or water, or chemical damage. Unless otherwise specified, plant diseases in this specification refer to diseases caused by bacteria, i.e., plant pathogenic bacteria. Unless otherwise specified, plant pathogenic bacteria in this specification refer to the aforementioned target bacteria, for example, bacteria of the genus Xanthomonas.

[0028] As used herein, "control" refers to prevention or treatment (eradication) (from the website of the Japan Agricultural Chemicals Association). Therefore, as used herein, "plant disease control" refers to the prevention of plant diseases, particularly target bacteria, or the treatment of plant diseases caused by target bacteria.

[0029] As used herein, the term "target plant" refers to a plant to which the plant disease control composition of the present invention described below is applied. This plant corresponds to a plant that has developed a specific plant disease due to infection with the target bacterium, or a plant that is at risk of infection with the target bacterium.

[0030] 1-3. Structure The lytic agent of the present invention comprises a bacteriophage. <First phage> The first phage is characterized by having a genomic DNA sequence including a specific base sequence, and the lytic agent of the present invention exhibits specific lytic activity against target bacteria.

[0031] (1-1) Genomic DNA The first phage has a genomic DNA sequence that is identical to the 42,933 bp nucleotide sequence shown in SEQ ID NO: 1, or the nucleotide sequence shown in SEQ ID NO: 1 in which one or more nucleotides have been added, deleted, and / or substituted, or is different from the nucleotide sequence shown in SEQ ID NO: 1 by 92.15% or more, 92.2% or more, 92.3% or more, 92.5% or more, 93% or more, 93.5% or more, 94% or more, 94.5% or more, 95% or more, 95.5% or more, 96% or more, 96.5% or more, 97% or more, 97.5% or more, 98% or more, 99% or more, 10 ... The base sequence has a sequence identity of 8.5% or more, 99% or more, or 99.5% or more, a base sequence that has a sequence identity of 99.01% or more, 99.05% or more, 99.1% or more, 99.2% or more, 99.3% or more, 99.4% or more, 99.5% or more, 99.6% or more, 99.7% or more, 99.8% or more, or 99.9% or more when aligned with the base sequence shown in SEQ ID NO: 1, and further has a base sequence that hybridizes under highly stringent conditions to a base sequence complementary to the base sequence shown in SEQ ID NO: 1.

[0032] In the case of a long genomic DNA sequence, it is not easy to align the entire range to obtain the comparison range. The comparison range (hereinafter sometimes referred to as Query Coverage) is most preferably 100% of the entire genome of the first phage, but may also be 99% or more, 98% or more, 97% or more, 96% or more, 95% or more, 94% or more, 93.5% or more, or 93% or more.

[0033] As used herein, "plurality" refers to 2 to 10, for example, 2 to 7, 2 to 5, 2 to 4, or 2 to 3.

[0034] As used herein, "(nucleotide) sequence identity" refers to a numerical value indicating the percentage of sites with the same type of base within the comparison range of two nucleotide sequences. Even when the lengths of the two nucleotide sequences are different, nucleotide sequence identity can be calculated by aligning the sequences to maximize the degree of base identity within the comparison range. A representative algorithm for such analysis is BLAST, although not limited thereto. BLAST is available in a variety of software and web services. For example, nucleotide sequence identity can be easily calculated using the genetic information processing software GENETYX (https: / / www.genetyx.co.jp / ) or the NCBI BLAST server (https: / / blast.ncbi.nlm.nih.gov / Blast.cgi). In addition to BLAST, there are also algorithms such as FASTA, which can be used as long as they can calculate reasonable identity; the method used is not particularly limited.

[0035] The term "highly stringent conditions" refers to environmental conditions that make it difficult for nonspecific hybridization to occur. Under highly stringent conditions, a nucleic acid having a target nucleotide sequence can form a hybrid, but a nucleic acid having a nonspecific nucleotide sequence cannot substantially form a hybrid. Generally, highly stringent conditions refer to conditions of low salt concentration and high temperature. A low salt concentration refers to, for example, 15 mM to 750 mM, preferably 15 mM to 500 mM, 15 mM to 300 mM, or 15 mM to 200 mM. Furthermore, a high temperature refers to, for example, 50 to 68°C or 55 to 70°C. A specific example of highly stringent conditions is washing after hybridization at 65°C with 0.1×SSC and 0.1% SDS.

[0036] From another perspective, since phages are viruses, it is conceivable that mutations such as substitutions, deletions, and insertions may occur in the genomic DNA when amplifying the phage of the present invention. As long as the degree of such mutations is within the above-mentioned range relative to the entire genomic DNA and the lytic function of the phage is maintained, even if mutations occur, they are included in the present invention.

[0037] Depending on the software or analysis server, an index of sequence identity may be expressed using, for example, average nucleotide identity (ANI), and these may also be used. It is not easy to align and compare the entire range of long phage genomic DNA. Therefore, the above-mentioned sequence identity may be achieved within the range automatically aligned by the software or web service. For example, in analysis using the NCBI-provided BLAST server, the query sequence and subject sequence are automatically aligned (often referred to herein as "alignment") to the maximum possible extent to determine the comparison range. The sequence identity within this comparison range is calculated, and the ratio of the comparison range to the entire range of the query sequence may be calculated as a value called Query Cover.

[0038] These values ​​may vary depending on the selection of the query and target sequences. To briefly explain this point, let us take the example of a first sequence consisting of sequence A and a second sequence consisting of sequence A and sequence B of the same length. If the shorter first sequence is used as the query sequence and the longer second sequence is used as the target sequence, the comparison range is sequence A, which is the entire length of the first sequence, so the calculated Query Coverage value is 100%. Furthermore, since sequence A in the first and second sequences is identical, the sequence identity value is 100%. Conversely, if the longer second sequence is used as the query sequence and the shorter first sequence is used as the target sequence, the sequence identity value will be 100% as before, but since sequence A occupies only half of the second sequence, the Query Coverage value will be 50%.

[0039] In such cases, the sequence identity of the base sequences in the entire range of the aligned base sequences (entire range sequence identity) can be estimated based on the results. For example, the estimated value of sequence identity in the entire range can be obtained by multiplying the Query Cover value by the value of sequence identity in the aligned range (sequence identity in the aligned range). In this case, further corrections, such as incorporating expected sequence identity in ranges other than the aligned range, may be made to improve the accuracy of the estimated value.

[0040] Phage genomic DNA can be packaged in either a linear or circular form. Next-generation genome sequencers determine the sequence by fragmenting the genomic DNA, reading the base sequence of each fragment, and then connecting the fragments. Phages are often assembled without a reference genomic DNA sequence (de novo assembly). Therefore, it is difficult to unambiguously determine the start and end of the analyzed genome (Merrill, B.D., et al. BMC Genomics, 2016 17, 679). The start and end of the genome sequences being compared can be different, and this is automatically taken into account when analyzing using software or analysis servers.

[0041] Among Xanthomonas bacteria, Xanthomonas arboricola, Xanthomonas citri, and Xanthomonas campestris are particularly preferred as target bacteria for the first phage, although they are not particularly limited thereto. Specific examples of Xanthomonas arboricola suitable as target bacteria for the first phage include Xanthomonas arboricola pv. pruni, which has the pathotype pruni, and Xanthomonas arboricola pv. juglandis, which has the pathotype juglandis. Specific examples of Xanthomonas citri suitable as target bacteria for the first phage include Xanthomonas citri subsp. citri. Specific examples of Xanthomonas campestris suitable as the target bacterium of the first phage include Xanthomonas campestris pv. vesicatoria, which has the pathotype vesicatoria, and Xanthomonas campestris pv. vitians, which has the pathotype vitians.

[0042] (1-2) Effects The lytic agent of the present invention containing the first phage can exhibit lytic activity against bacteria of the genus Xanthomonas and can be used to treat plant diseases.

[0043] <Second Phage> The second phage is characterized by having a genomic DNA sequence of a specific length containing a specific base sequence, and the lytic agent of the present invention exhibits specific lytic activity against the target bacterium.

[0044] (2-1) Genomic DNA The second phage has a genomic DNA sequence that is identical to the 35,321 bp nucleotide sequence shown in SEQ ID NO: 2, or the nucleotide sequence shown in SEQ ID NO: 2 in which one or more nucleotides have been added, deleted, and / or substituted, or is identical to the nucleotide sequence shown in SEQ ID NO: 2 by 90% or more, 90.5% or more, 91% or more, 91.5% or more, 92% or more, 92.5% or more, 93% or more, 93.5% or more, 94% or more, 94.5% or more, 95% or more, 95.5% or more, 96% or more, 96.5% or more, 97% or more, 97.5% or more, 98% or more, 98.5% or more. a base sequence having 99% or more, or 99.5% or more sequence identity; a base sequence having 95.0% or more, 95.5% or more, 96.0% or more, 96.5% or more, 97.0% or more, 97.5% or more, 98.0% or more, 98.5% or more, 99% or more, 99.5% or more, 99.6% or more, 99.7% or more, 99.8% or more, or 99.9% or more sequence identity when aligned with the base sequence shown in SEQ ID NO: 2; and a base sequence that hybridizes under highly stringent conditions to a base sequence complementary to the base sequence shown in SEQ ID NO: 2.

[0045] It is not easy to cover the entire range of a long genomic DNA sequence. The comparison range (hereinafter sometimes referred to as "Query Coverage") is most preferably 100% of the entire genome of the second phage, but may also be 99% or more, 98% or more, 97% or more, 96% or more, 95% or more, 94% or more, or 93% or more.

[0046] The total length of the genomic DNA sequence of the second phage is 40,000 bases or less. For example, the total length of the genomic DNA sequence is 40,000 bases or less, 39,500 bases or less, 39,000 bases or less, 38,500 bases or less, 38,000 bases or less, 37,500 bases or less, 37,000 bases or less, 36,500 bases or less, 36,000 bases or less, 35,900 bases or less, 35,800 bases or less, 35,700 bases or less, 35,600 bases or less, 35,500 bases or less, or 35,400 bases or less.

[0047] Among the Xanthomonas bacteria listed in the definition section above, Xanthomonas arboricola and Xanthomonas campestris are particularly preferred as target bacteria for the second phage, although they are not particularly limited thereto. Specific examples of Xanthomonas arboricola suitable as target bacteria for the second phage include Xanthomonas arboricola pv. pruni, which has the pathotype pruni, and Xanthomonas arboricola pv. juglandis, which has the pathotype juglandis. Specific examples of Xanthomonas campestris suitable as target bacteria for the second phage include Xanthomonas campestris pv. vesicatoria, which has the pathotype vesicatoria, Xanthomonas campestris pv. vitians, which has the pathotype vitians, and Xanthomonas campestris pv. campestris, which has the pathotype campestris.

[0048] (2-2) Effects The lytic agent of the present invention containing the second phage can exhibit lytic activity against bacteria of the genus Xanthomonas and can be used to treat plant diseases.

[0049] <Third Phage> The third phage is characterized by having a genomic DNA sequence containing a specific base sequence, and the lytic agent of the present invention exhibits specific lytic activity against target bacteria.

[0050] (3-1) Genomic DNA The third phage has a genomic DNA sequence that is identical to the 43,601 bp nucleotide sequence shown in SEQ ID NO: 3, or the nucleotide sequence shown in SEQ ID NO: 3 in which one or more nucleotides have been added, deleted, and / or substituted, or is identical to the nucleotide sequence shown in SEQ ID NO: 3 by 90% or more, 90.5% or more, 91% or more, 91.5% or more, 92% or more, 92.5% or more, 93% or more, 93.5% or more, 94% or more, 94.5% or more, 95% or more, 95.5% or more, 96% or more, 96.5% or more, 97% or more, 97.5% or more, The base sequence has a sequence identity of 98% or more, 98.5% or more, 99% or more, or 99.5% or more, a base sequence that has a sequence identity of 96.9% or more, 97.0% or more, 97.5% or more, 98.0% or more, 98.5% or more, 99% or more, 99.5% or more, 99.6% or more, 99.7% or more, 99.8% or more, or 99.9% or more when aligned with the base sequence shown in SEQ ID NO: 3, and further has a base sequence that hybridizes under highly stringent conditions to a base sequence complementary to the base sequence shown in SEQ ID NO: 3.

[0051] It is not easy to cover the entire range of a long genomic DNA sequence. The comparison range (hereinafter sometimes referred to as "Query Coverage") is most preferably 100% of the entire genome of the third phage, but may also be 99% or more, 98% or more, 97% or more, 96% or more, 95% or more, 94% or more, 93% or more, 92% or more, 91% or more, 90% or more, 89% or more, or 88% or more.

[0052] Among the Xanthomonas bacteria listed in the definition section above, Xanthomonas arboricola and Xanthomonas campestris are preferred target bacteria for the third phage, although there are no particular limitations thereon. Specific examples of Xanthomonas arboricola suitable as target bacteria for the third phage include Xanthomonas arboricola pv. juglandis, which has the pathotype juglandis. Specific examples of Xanthomonas campestris suitable as target bacteria for the third phage include Xanthomonas campestris pv. vesicatoria, which has the pathotype vesicatoria, Xanthomonas campestris pv. vitians, which has the pathotype vitians, and Xanthomonas campestris pv. campestris, which has the pathotype campestris.

[0053] (3-2) Effects The lytic agent of the present invention can exhibit lytic activity against bacteria of the genus Xanthomonas and can be used to treat plant diseases.

[0054] 2. Plant Disease Control Composition 2-1. Overview A second aspect of the present invention is a composition, particularly a composition usable for controlling plant diseases. The composition of the present invention is characterized by containing the lytic agent described in the first aspect as an active ingredient.

[0055] The composition of the present invention can provide a sustainable pesticide for bacterial plant diseases that is safe for humans, does not cause phytotoxicity to the environment, and can specifically prevent or treat target plant diseases when used to control plant diseases.

[0056] In this specification, the term "plant disease control composition" refers to the case where the composition of the present invention is used for plant disease control.

[0057] 2-2. Composition 2-2-1. Constituent Components The composition of the present invention contains, as an active ingredient, the bacteriophage that is the lytic agent according to the first aspect as an essential component. It may also contain an agriculturally acceptable carrier and / or medium to the extent that it does not inhibit or suppress the lytic activity of the phage against target bacteria. If necessary, it may further contain other active ingredients. Each of the constituent components will be specifically described below.

[0058] (1) Active ingredient (lytic agent) The composition of the present invention contains, as an essential active ingredient, the lytic agent described in aspect 1. In the plant disease control composition, this active ingredient lyses the target bacterium of the present invention, thereby making it possible to prevent or treat plant diseases caused by the target bacterium.

[0059] The specific constitution of the lytic agent is described in detail in the first embodiment, and therefore will not be described here.

[0060] When used for plant disease control, the amount of active ingredient contained per unit amount in the composition depends on various conditions, such as the formulation, type of plant pathogenic bacterium, type of target plant, application location, and application method. It is preferable that the phage, which is the active ingredient, is contained in an amount sufficient to contact and infect plant pathogenic bacteria that have infected the target plant. Therefore, the amount of the lytic agent contained in the plant disease control composition of the present invention can be determined, taking into account various conditions, within the scope of common general technical knowledge in the field, so that the amount of the lytic agent contained in the plant disease control composition of the present invention is effective against the target bacteria after application.

[0061] (2) Agriculturally acceptable carriers and media The term "agriculturally acceptable carriers and / or media" refers to substances that facilitate the application of the composition, can maintain the viability and infectivity of the phage, which is the active ingredient, and / or can control the rate of action, and that have no or very little harmful effects on the environment, such as soil and water quality, when applied outdoors, and that are no or very little harmful to animals, especially humans.

[0062] (2-1) Carrier Specific examples of agriculturally acceptable carriers include surfactants, protective agents, and excipients. If desired, small amounts of wetting agents, emulsifiers, pH buffers, and the like may also be used. The carrier may be mixed in advance or may be mixed just before application.

[0063] Surfactants have the effect of improving the physicochemical properties of compositions on plants, such as wetting, emulsifying, dispersing, penetrating, adhesive, defoaming, and spreading properties. Surfactants can be used as the main component of agricultural chemical adjuvants called wetting agents. Examples of wetting agents include nonionic surfactants, combinations of nonionic and anionic surfactants, paraffin-based surfactants, and polyoxyethylene resin acid esters. More specific examples include polyoxyethylene alkyl ether compounds, polyoxyethylene fatty acid ester compounds, lignin sulfonate compounds, naphthylmethanesulfonate compounds, alkyl sulfosuccinate compounds, and tetraalkylammonium salt compounds.

[0064] In the case of phages, the protective agent is expected to have the effect of reducing damage caused by ultraviolet rays, etc. Examples of the protective agent include skim milk, casein, gelatin, etc.

[0065] Examples of excipients include glucose, lactose, sucrose, gelatin, starch, malt, and wheat flour.

[0066] (2-2) Solvent Specific examples of agriculturally acceptable solvents include water (including aqueous solutions), buffers, and liquid media. The solvent is preferably a sterile liquid.

[0067] (3) Other Active Ingredients In addition to the lytic agent described in the first aspect, the composition of the present invention may contain one or more other active ingredients having the same and / or different pharmacological action as long as they do not affect the lytic activity of the phage constituting the lytic agent.

[0068] The type of other active ingredient is not limited. For example, it may be a phage having lytic activity against the same and / or different bacteria. Examples of phages having lytic activity against the same bacteria include other phages that specifically recognize and bind to Xanthomonas bacteria, similar to the phages constituting the lytic agent described in the first aspect. For example, even if the target bacteria is the same, a synergistic or complementary effect of lytic activity can be expected by combining phages that recognize different cell surface receptors.

[0069] The type of such other phages that specifically recognize bacteria of the genus Xanthomonas and have bacteriolytic activity is not particularly limited, and specific examples include phages whose genomic DNA contains the nucleotide sequence set forth in any one of SEQ ID NOs: 4 to 11, and mutants and modified forms thereof.

[0070] The plant disease control composition of the present invention can contain, in addition to the lytic agent described in the first aspect, one or more other phages that specifically recognize the Xanthomonas bacteria specifically exemplified above and have lytic activity in combination as active ingredients.

[0071] In the above, it is preferable that the sequence identity of the amino acid sequences is 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more. As already mentioned, in this specification, "plurality" refers to 2 to 10, for example, 2 to 7, 2 to 5, 2 to 4, or 2 to 3.

[0072] Furthermore, "(amino acid) substitution" refers to substitution within a conservative amino acid group that has similar properties, such as charge, side chain, polarity, and aromaticity, among the 20 amino acids that constitute natural proteins. Examples include substitutions within the uncharged polar amino acid group with low-polarity side chains (Gly, Asn, Gln, Ser, Thr, Cys, Tyr), branched-chain amino acids (Leu, Val, Ile), neutral amino acids (Gly, Ile, Val, Leu, Ala, Met, Pro), neutral amino acids with hydrophilic side chains (Asn, Gln, Thr, Ser, Tyr, Cys), acidic amino acids (Asp, Glu), basic amino acids (Arg, Lys, His), and aromatic amino acids (Phe, Tyr, Trp). Amino acid substitutions within these groups are preferred because they are known to be less likely to alter the properties of polypeptides.

[0073] Furthermore, as used herein, "amino acid sequence identity" refers to a numerical value indicating the proportion of sites in which the type of amino acid residue is the same within the comparison range of two amino acid sequences. Even if the lengths of the two amino acid sequences are different, amino acid sequence identity can be calculated by aligning the sequences so that the degree of amino acid identity within the comparison range is maximized. Algorithms that can be used for such analyses include, but are not limited to, the previously mentioned algorithms such as BLAST.

[0074] Other active ingredients may include insecticides, herbicides, fertilizers (e.g., urea, ammonium nitrate, superphosphate), and, if necessary, known chemical pesticides, antibiotics, and biological pesticides.

[0075] 2-2-2. Dosage Form When used as a plant disease control composition, the composition of the present invention may be in any dosage form as long as it can maintain the infection site of the target bacterium on the target plant, the ability to colonize the target plant, and / or the ease with which the phage, the active ingredient, can infect the target bacterium. For example, the plant disease control composition may be suspended in an appropriate solution in the form of a liquid or wettable powder, or may be mixed with a carrier and solidified into a solid powder, granule, or gel. For example, when the infection site of the target bacterium on the target plant is the leaves, flowers, fruits, stems, branches, or trunk above ground, a liquid, wettable powder, or gel formulation is preferred, as these formulations are widely distributed over the infection site and have high colonization properties. On the other hand, when the infection site of the target bacterium is the roots or rhizomes below ground, a powder or granule formulation is preferred, as they can be slowly released in the soil and exert a sustained effect on the infection site.

[0076] 2-3. Application Method When the composition of the present invention is used as a plant disease control composition, any method known in the art may be used as long as it can apply the plant disease control composition to a target plant, and is not particularly limited. Since the phage, which is the active ingredient of the plant disease control composition, can invade the entire plant surface, such as the stems, leaves, and roots of a target plant, it can be applied by a method appropriate for the purpose. For example, if the application site is an above-ground part such as the stems and leaves, the plant disease control composition can be applied so that it directly contacts the application site. Direct contact can be achieved by, for example, painting, spraying, dusting, or immersion of the plant disease control composition on the application site. Application is particularly preferably carried out to a site of the target plant that is infected or at risk of infection by the target bacterium. Furthermore, if the application site is an underground part such as the roots, the composition can be applied indirectly by adding it to the soil, or to a medium if the application site is a culture medium. The term "soil" as used herein is not particularly limited as long as it is soil in which the target plant can grow. Typically, planting soil containing appropriate nutrients and having an appropriate pH value is used. The location of the soil is not important. Furthermore, the term "culture medium" refers to an artificially prepared culture medium for planting the target plant. It may be a solid medium such as an agar medium, or a liquid medium. Examples of culture medium include isolation beds, root-restricted pots, and seedbeds. The composition of the culture medium may be any known medium composition in the art. It can be selected appropriately depending on the type of plant, etc.

[0077] 2-4. Target Plants The target plants of the plant disease control composition of the present invention are not particularly limited in type, as long as they are plants that can develop plant diseases caused by the target bacterium of the present invention. They may be either angiosperms or gymnosperms. Furthermore, they may be herbaceous or woody plants. Suitable examples of target plants include agriculturally important plants, such as crop plants such as cereals, vegetables, and fruits, and ornamental plants. Specific examples of monocotyledonous plants include plants from the Poaceae family (e.g., rice, wheat, barley, corn, sugarcane, sorghum, sorghum, and turfgrass), plants from the Musaceae family (e.g., bananas), plants from the Amaryllidaceae family (e.g., leeks, onions, garlic, and chives), and plants from the Liliaceae family (e.g., lilies and tulips). In addition, dicotyledonous plants include Brassicaceae plants (e.g., cabbage, radish, Chinese cabbage, rapeseed), Asteraceae plants (e.g., lettuce, burdock, chrysanthemum), Fabaceae plants (e.g., soybean, peanut, pea, kidney bean, lentil, chickpea, broad bean, licorice), Solanaceae plants (e.g., tomato, eggplant, potato, tobacco, bell pepper, capsicum, petunia), and Rosaceae plants (e.g., strawberry, apple, pear, peach, loquat, almond, plum, rose, plum). , cherry blossom), Cucurbitaceae plants (e.g., cucumber, gourd, pumpkin, melon, watermelon), Anacardiaceae plants (e.g., mango, pistachio, cashew nut), Lauraceae plants (e.g., avocado), Rutaceae plants (e.g., mandarin orange, grapefruit, lemon, yuzu), Convolvulaceae plants (e.g., sweet potato), Theaceae plants (e.g., tea plant), and Vitaceae plants (e.g., grape).

[0078] 2-5. Target Plant Diseases The target plant diseases to which the plant disease control composition of the present invention is applied include any plant disease caused by the target bacterium of the present invention. Preferably, the plant disease is caused by a bacterium of the genus Xanthomonas. Examples include bacterial spot found on peaches, bacterial blight found on walnuts, bacterial pustule found on soybeans, angular leaf spot found on strawberries, bacterial blight found on tomatoes, bell peppers, lettuce, black rot found on cabbage, Chinese cabbage, broccoli, bacterial canker found on oranges and grapefruit, angular leaf spot found on cotton, and bacterial leaf blight found on rice.

[0079] 3. Plant Disease Control Method 3-1. Overview A third aspect of the present invention is a plant disease control method. The plant disease control method of the present invention is characterized by controlling plant diseases in a target plant by applying the plant disease control composition described in the second aspect to the target plant.

[0080] According to the method for controlling plant diseases of the present invention, plant diseases caused by bacteria, particularly bacteria of the genus Xanthomonas, can be controlled in target plants.

[0081] 3-2. Method The plant disease control method of the present invention includes a contact step as an essential step.

[0082] The "contact step" is a step of contacting a target plant with the plant disease control composition according to the second aspect. This step basically conforms to "2-3. Application method" for the plant disease control composition according to the second aspect.

[0083] In this aspect, "contact" refers to contact between the plant disease control composition and the target plant. More specifically, it refers to contact of the lytic agent according to the first aspect, i.e., the phage, which is the active ingredient of the plant disease control composition, with the plant body of the target plant, preferably with a site infected or at risk of infection by the target bacterium. The purpose of this step is to infect the target bacterium with the phage, which is the active ingredient, thereby lysing the target bacterium. As a result, the effect of controlling plant diseases caused by the target bacterium can be exerted.

[0084] Contact may be either direct or indirect. In this embodiment, direct contact refers to direct contact of the plant disease control composition with a predetermined site of the target plant. Specifically, for example, this refers to applying, spraying, dusting, or immersing the liquid or gel plant disease control composition on the target plant. In this case, the plant body to be contacted is mainly the leaves, flowers, fruits, stems, branches, and / or trunk. On the other hand, indirect contact in this embodiment refers to contact of the plant disease control composition with a predetermined site of the target plant via an intermediary. For example, this refers to applying a granular plant disease control composition to the soil around the roots of the target plant. The phage, which is the active ingredient, is transported via water in the soil and eventually absorbed by the roots.

[0085] 3-3. Effects. Phages, the active ingredient of the composition obtained by the present invention, can efficiently kill target bacteria, thereby helping to prevent and suppress diseases caused by target bacteria. Furthermore, their specific bacteriolytic activity allows for the detection and identification of target bacteria, enabling disease diagnosis. While copper compounds and antibiotics have traditionally been used to treat Xanthomonas bacteria, these compounds can cause phytotoxicity and disrupt the balance of the microbiota. For example, some strains of Pseudomonas fluorescens have been demonstrated to promote plant growth (Haas D., Defago G., Nature Reviews in Microbiology, 2005, 3(4), 307-19). Therefore, copper compounds and antibiotics are likely to kill bacteria that are symbiotic with plants. However, because phages are derived from biological sources, no phytotoxicity has been reported, and their high specificity limits their impact on the balance of the microbiota.

[0086] 4. Method for Identifying Xanthomonas Bacteria 4-1. Overview A fourth aspect of the present invention is a method for identifying Xanthomonas bacteria. The identification method of the present invention is characterized by identifying Xanthomonas bacteria by utilizing the host specificity of the phage constituting the lytic agent described in the first aspect.

[0087] According to the present invention, it is possible to determine whether or not an unidentified plant pathogenic bacterium that has caused a plant disease is a bacterium of the genus Xanthomonas, and to identify it.

[0088] The identification method of the present invention includes a culturing step, a mixing step, a mixture culturing step, and a determination step as essential steps, and an isolation step as a selection step. Each step will be explained below.

[0089] (1) Isolation Step The "isolation step" is a step of isolating a test bacterium from plant tissue infected with a plant disease. This step is a selection step and may be performed as needed.

[0090] The term "test bacterium" refers to a plant pathogenic bacterium to be subjected to the method for identifying Xanthomonas bacteria according to the fourth aspect of the present invention, the species of which has not yet been identified.

[0091] The plant tissue may be any part of the plant affected by the plant disease, but preferably a part where the symptoms of the plant disease are clearly visible. For example, in the case of a peach affected by bacterial peach hole, the affected leaves may be used.

[0092] To isolate the test bacterium from harvested plant tissue, the diseased specimen may be immersed in a solvent such as water and extracted, optionally fragmented or crushed during extraction, and the extract may then be streaked onto an agar medium to pick a single colony.

[0093] (2) Culturing Step The "culturing step" is a step of culturing the isolated test bacterium to obtain a culture. The test bacterium may be cultured by a method known in the art.

[0094] The term "culture" refers to a substance obtained by culturing a test bacterium, and may be either liquid or solid.

[0095] Because the test bacterium in this step is unidentified, it is desirable to use a medium capable of culturing a wide range of plant pathogenic bacteria. A medium capable of culturing at least the Xanthomonas bacteria, the bacterium to be identified in this invention, is used. Such a medium may contain one or more components selected from the group consisting of proteolytic enzyme hydrolysates such as peptone and tryptone, biological extracts such as potato dextrose and yeast extract, amino acids such as glutamic acid or their salts, sugars such as glucose and sucrose, and inorganic salts such as sodium chloride, magnesium chloride, and potassium dihydrogen phosphate. Specific media and compositions include LB medium (tryptone, yeast extract, sodium chloride), YPG medium (yeast extract, peptone, glucose), PD medium (potato dextrose), and Suwa medium with peptone (sucrose, glutamic acid, peptone).

[0096] The isolated test bacterium is inoculated into the medium and cultured under appropriate culture conditions. Culture conditions include, for example, 20-40°C, 20-30°C, 22-28°C, or 24-26°C, with stirring to obtain a culture. The culture time is not limited, but may be, for example, until the turbidity at a wavelength of 600 nm reaches approximately 1.0. This step yields a culture solution of the test bacterium. The culture may also be a multi-stage culture consisting of two or more stages. For example, a soft agar-containing liquid medium may be added to the culture solution obtained after culture in a liquid medium, and the culture solution may be poured onto a solid medium such as an agar medium to solidify, after which further culture may be performed.

[0097] (3) Mixing Step The "mixing step" is a step of mixing the culture obtained in the culturing step with the lytic agent according to the first aspect to obtain a mixture.

[0098] The "mixture" refers to a mixture of a culture and a lysis agent, and may be either liquid or solid.

[0099] The method of mixing the culture and the lytic agent is not particularly limited as long as the lytic agent can be mixed. The lytic agent described in the first aspect may be administered in a solid state or in a liquid state suspended in water or a liquid medium.

[0100] If the culture and lysing agent are both liquid, the volume ratio of culture to lysing agent may be 1:9, 2:8, 3:7, 4:6, 5:5, 6:4, 7:3, 8:2, or 9:1. After administration, the culture and lysing agent may be thoroughly mixed by stirring or other means. On the other hand, when a soft agar-containing liquid medium is layered as described above, the culture is solid. In this case, the lysing agent may be dropped onto a solid culture such as a gel surface, allowing the two to be mixed on the solid medium to obtain a mixture.

[0101] (4) Mixture Cultivation Step The "mixture cultivation step" is a step of culturing the mixture under predetermined conditions.

[0102] When culturing the mixture, a soft agar-containing liquid medium may be added to the mixture, poured onto a solid medium such as an agar medium, and allowed to solidify, followed by further culturing.

[0103] The basic procedure of this step is similar to that of the culturing step described above. In this step, although not limited thereto, it is preferable to carry out culturing based on the so-called plaque assay method so as to easily confirm whether or not the test bacterium has been lysed by the phage constituting the lytic agent in the determination step described below. For example, a portion of the mixture may be mixed with a soft agar medium of the same composition, and then, before the soft agar medium solidifies, the mixture may be poured onto an agar medium of the same composition and spread over the entire medium. The mixture may then be cultured under the same conditions as in the culturing step described above.

[0104] (5) Determination Step The "determination step" is a step of determining that the test bacterium is a bacterium of the genus Xanthomonas when the test bacterium is lysed after the culture step.

[0105] The determination of the presence or absence of bacteriolysis is not limited, but for example, in the case of a plaque assay, the determination can be made based on the presence or absence of plaque formation. If plaques are present on the solidified soft agar medium after the aforementioned mixture culture step, this indicates that the test bacterium has been lysed by infection with the phage constituting the bacteriolytic agent of the present invention. Therefore, the test bacterium can be determined to be a bacterium of the genus Xanthomonas. On the other hand, if the test bacterium grows entirely on the agar medium and no plaques are present at all, the test bacterium can be determined not to be a bacterium of the genus Xanthomonas.

[0106] For more accurate determination, a negative control may be prepared by mixing with a medium containing no lytic agent in the mixture culture process, and / or a positive control may be prepared by using identified Xanthomonas bacteria in the culture process instead of the test bacteria, and it may be confirmed that no plaques form in the negative control and that plaques are observed in the positive control.

[0107] 4-3. Effects According to the method for identifying Xanthomonas bacteria of the present invention, it is possible to identify whether or not a plant disease is caused by Xanthomonas bacteria.

[0108] Furthermore, the method for identifying Xanthomonas bacteria of the present invention makes it possible to detect whether or not Xanthomonas bacteria are present in the lesions of a plant that has developed a plant disease that is suspected to be caused by Xanthomonas bacteria.

[0109] Example 1: Isolation of a novel bacteriophage and its lytic activity (1) (Objective) A novel bacteriophage having lytic activity against pathogenic bacteria that cause plant diseases is isolated, and its lytic activity against plant pathogenic bacteria is verified.

[0110] (Methods and Results) (1) Obtaining and Cultivating Plant Pathogenic Bacteria In this example, all plant pathogenic bacteria were obtained from the National Agriculture and Food Research Organization (NARO). The bacteria used in this example are listed in Table 2 along with their NARO deposit number.

[0111]

[0112] For control purposes, a strain of environmentally beneficial Pseudomonas fluorescens, which has been reported to have plant growth promoting effects, was obtained from NCIMB, a research institute within the UK National Culture Collection (UKNCC) (NCIMB-ID: 10460).

[0113] For culturing Xanthomonas and Pseudomonas fluorescens species, a liquid medium (YPG Broth) was used, prepared by dissolving 1 g of peptone, 1 g of yeast extract, and 2 g of glucose in 1 L of HO and autoclaving. For agar medium, 15 g of agar per liter of the above-mentioned broth (YPG Broth) was added and autoclaved (referred to as "YPG Agar" when YPG Broth was used). Furthermore, for the soft agar medium (Top Agar) layered on top of the agar medium, 5 g of agarose per liter of the above-mentioned broth was added. This autoclaved Top Agar was stored at approximately 50°C and used as needed.

[0114] Each of the above strains, delivered in dry powder form, was suspended in 0.1 mL of broth and then streaked on agar (YPG agar) at 25°C to isolate single colonies. The isolated colonies were inoculated into broth and cultured with shaking at 25°C to prepare the preculture medium. For the main culture, the preculture medium was inoculated into broth and cultured at 25°C for 10 to 30 hours until the turbidity (optical density 600 nm) reached approximately 1.0. The culture medium after cultivation was used as is as the bacterial suspension.

[0115] (2) Isolation and Purification of the First Phage. The novel phage was isolated from natural wastewater or soil obtained in Japan. The phage was isolated using a conventional plaque assay method. First, wastewater from ponds or lakes, or wastewater obtained by suspending soil in water, was filtered through a 0.45 μm filter to prepare a phage-containing solution. Equal amounts of the bacterial solution and the phage-containing solution were then mixed and left at room temperature for approximately 10 minutes. Next, 0.2 mL of the bacteria / phage mixture was added to 3 mL of Top Agar, quickly mixed using a vortex mixer, and poured onto the agar. After the Top Agar solidified, the mixture was incubated at 25°C for approximately 12 hours. Lytic plaques were formed on the bacterial lawn formed by the incubation. The gel from the plaques was then aspirated using a cut tip, and phages with lytic activity against Xanthomonas bacteria were isolated. Thereafter, the phage-containing liquid containing the isolated phages at a high concentration was used instead of the wastewater, and the procedure was repeated to purify the phages.

[0116] Using a method for detecting lytic plaques formed on soft agar plates containing amplified strains of any of the above, three new phages were isolated from natural wastewater and soil. The novel phage isolated in Example 1 is designated as the "first phage."

[0117] The isolated phages were suspended in SM Buffer and passed through a 0.2 μm filter to recover the phage-containing solution. This phage-containing solution was mixed with the bacterial solution under the same conditions as above, and the phages were isolated again. This procedure was repeated several times to further purify the phages. The composition of SM Buffer is shown in Table 3.

[0118]

[0119] (3) Amplification and Purification of the First Phage To amplify and purify the isolated and purified first phage, a plate lysate (PL) method, an amplification method using a plaque assay, was performed. The bacteria / phage mixture was prepared so that many plaques would form on the agar, mixed with Top Agar, and then spread onto YPG Agar and cultured. Then, 3 mL of SM Buffer was added to the Top Agar on which the plaques had formed, and the mixture was shaken at 25°C for approximately 30 minutes. The supernatant was then passed through a 0.2 μm filter to recover the phage-containing solution.

[0120] The first phage was purified by adding 1 g of PEG 6000 (final concentration: 10%) and 0.4 g of NaCl (final concentration: 4%) to 10 mL of the recovered solution and dissolving the solution. The solution was then rotated overnight at 4°C using a rotator. The solution was then centrifuged at 15,000 x g at 4°C for 60 minutes, and the supernatant was removed. The recovered pellet was resuspended in 0.5 mL of SM Buffer. Next, 0.5 mL of chloroform was added, the solution was vigorously mixed, and the solution was left on ice for 6 hours. After centrifugation at 8,000 x g at 4°C for 10 minutes, the upper layer was carefully collected to obtain the purified phage solution. The concentration of the purified phage solution is generally expressed as a titer (PFU / mL) based on the number of plaques (Plaque Forming Units, PFU) in a plaque assay, and this titer serves as an index of bacteriolytic activity. The titer of the prepared first phage purified solution was determined by plaque assay using an appropriately diluted solution. 8 It was confirmed that the PFU / mL or more.

[0121] (4) Evaluation of the Host Range of the First Phage The host range of the first phage was evaluated using a spot test. 0.1 mL of the bacterial suspension alone was added to 3 mL of Top Agar, mixed, and poured onto the agar, allowing it to spread over the entire plate and solidify. In addition to the bacterial suspensions of each Xanthomonas bacterium listed in Table 2 prepared in (1) above, a control bacterial suspension of Pseudomonas fluorescens was also prepared. Approximately 5 μL of the purified phage solution was then added dropwise and incubated at 25°C for approximately 12 hours. If a clear circle (approximately 1 cm in diameter) formed at the drop location on the plate where the bacterial lawn had formed, the added phage was determined to have lytic activity against that bacterial strain.

[0122] Examples of results are shown in Figures 1 and 2. If the first phage exhibits lytic activity, only the area of ​​the bacterial lawn formed on the plate where the phage purified solution was dropped will become transparent. One type of first phage obtained by the present invention exhibited lytic activity against all strains belonging to the three bacterial species listed in Table 2: Xanthomonas arboricola (including pv. pruni and pv. juglandis), Xanthomonas campestris (including pv. vesicatoria and pv. vitians), and Xanthomonas citri. On the other hand, it was also confirmed that it did not exhibit lytic activity against Pseudomonas fluorescens. While there have been reports of phages active against two or more species of Xanthomonas, the above-described pattern has not been reported (Nakayinga R. et al., BMC Microbiology, 2021, 21:291). This suggests that the first isolated phage exhibits broad lytic activity against Xanthomonas bacteria.

[0123] This result also indicates that the first phage may be applicable to various plant diseases, such as peach bacterial hole, walnut bacterial black spot, tomato bacterial spot, lettuce bacterial spot, and citrus canker, which are caused by Xanthomonas bacteria, and is expected to be highly valuable for industrial use.

[0124] (5) Genome Analysis of the First Phage The genomic DNA sequence of the first phage was determined and analyzed.

[0125] (i) Preparation and sequencing of genomic DNA of the first phage TURBO DNA-free TM The genome of the first phage was extracted using a kit (Thermo Fisher Scientific). Contaminating genomic DNA from the host bacterium was removed according to the kit's instructions. Subsequently, the phage coat molecules were degraded by Proteinase K treatment using a NucleoSpin® Virus (Machery-Nagel) according to the kit's instructions. After genomic DNA purification using a silica spin column, a genomic DNA solution of the first phage was prepared. The concentration of the genomic DNA was then measured using a Qubit dsDNA HS Assay kit (Thermo Fisher Scientific), and 50 μL of genomic DNA solution was prepared to a final concentration of 0.2 ng / μL. Subsequently, the genome of the first phage was fragmented and adapter sequences were added by PCR using a Nextera XT DNA Library Prep (Illumina) according to the kit's instructions. Next, electrophoresis was performed using an Agilent High Sensitivity DNA Kit (Agilent Technologies) and a Bioanalyzer (Agilent Technologies). The average bp size of the samples was measured and the DNA fragment concentration was determined. Finally, measurement samples were prepared using a Miseq Reagent kit (Illumina) according to the accompanying manual, and measurements were performed using a Miseq next-generation sequencer (Illumina). The obtained data was preprocessed (e.g., trimmed) using CLC genomics workbench (Qiagen), and then de novo assembly was performed to obtain contig sequences corresponding to the phage genome sequence.

[0126] (ii) Bioinformatics Analysis Based on Genome Sequence Information Based on the nucleotide sequence of the genomic DNA of the first phage obtained in (i) (SEQ ID NO: 1), a search for similar DNA sequences and confirmation of sequence identity was performed using the BLAST server provided by NCBI (https: / / blast.ncbi.nlm.nih.gov / Blast.cgi). A search for known sequences with high sequence identity over 90% or more of the full length (Query Cover) revealed that the sequence with the highest sequence identity was the genomic DNA sequence of Pseudomonas phage vB_Pae_TR (access code: OL802211.1), which shared 99.07% sequence identity over 93% of the full length of SEQ ID NO: 1.

[0127] The sequence identity is a value calculated for the range automatically aligned by the analysis server against the entire genome of the first phage. The range is displayed as the Query Cover, and the 99.07% sequence identity of vB_Pae_TR was calculated by limiting the region to 93% of the entire ΦX-33 genome. Therefore, while it is difficult to calculate the sequence identity for the entire genome, it is estimated to be at least lower than 99.07% and usually corresponds to a value equal to or lower than 93%.

[0128] It was revealed that the target bacterium of phage vB_Pae_TR, which has a genome with the above-mentioned known sequence, is a bacterium of the genus Pseudomonas. Therefore, it can be said that it was difficult to identify the target bacterium of the first phage isolated in this example based on its sequence identity with the genome sequence of a known phage. At the same time, it is highly likely that phages with higher full-length sequence identity than vB_Pae_TR (phages showing higher sequence identity over a wider range) have a similar host range to the first phage isolated in this example, i.e., phages that use a variety of Xanthomonas bacteria as host bacteria.

[0129] These results suggest that the first phage is a completely novel phage with a host range of the genus Xanthomonas, which has not been reported previously.

[0130] Example 2: Isolation of a novel bacteriophage and its lytic activity (2) (Objective) A novel bacteriophage having lytic activity against pathogenic bacteria that cause plant diseases is isolated, and its lytic activity against plant pathogenic bacteria is verified.

[0131] (Methods and Results) (1) Obtaining and Cultivating Plant Pathogenic Bacteria In this example, the target plant pathogenic bacteria were Xanthomonas bacteria, and all strains were obtained from the National Agriculture and Food Research Organization (NARO). The bacteria used in Examples 7 and 8 are listed in Table 4 along with their respective NARO deposit number (MAFF No.).

[0132]

[0133] For control purposes, a strain of Pseudomonas fluorescens, a bacterium of the genus Pseudomonas, was obtained from NCIMB, a research institute within the UKNCC (United Kingdom Microorganism Collection) (NCIMB-ID: 10460).

[0134] Xanthomonas bacteria and Pseudomonas fluorescens were cultured according to the method described in Example 1, "(1) Obtaining and culturing plant pathogenic bacteria."

[0135] (2) Isolation and Purification of the Second Phage The novel phage was isolated from natural wastewater or soil obtained in Japan. The isolation and purification methods were in accordance with the methods described in "(2) Isolation and Purification of the First Phage" in Example 1. As a result, one new phage was isolated from the natural wastewater and soil. This novel phage isolated in Example 2 is referred to as the "second phage."

[0136] The isolated phages were suspended in SM buffer and passed through a 0.2 μm filter to collect the phage-containing solution. This phage-containing solution was mixed with the bacterial solution under the above conditions, and the phages were isolated again. This procedure was repeated several times to purify the phages.

[0137] (3) Amplification and Purification of Second Phage The plate lysate (PL) method was carried out to amplify and purify the isolated and purified second phage. The specific method was in accordance with the method described in "(3) Amplification and Purification of Phage" in Example 1. The titer of the prepared purified second phage solution was determined by plaque assay using an appropriately diluted solution, and the titer was 10 8 It was confirmed that the PFU / mL or more.

[0138] (4) Evaluation of host range of second phage The host range of the second phage was evaluated by a spot test method. The basic procedure was in accordance with the method described in "(4) Evaluation of host range of first phage" in Example 1.

[0139] Examples of the results are shown in Figures 3 and 4. If the second phage exhibits lytic activity, only the area of ​​the bacterial lawn formed on the plate where the phage purified solution was dropped will become transparent. The second phage obtained by the present invention exhibited lytic activity against all of the Xanthomonas bacteria listed in Table 4. However, it did not exhibit lytic activity against Pseudomonas fluorescens. No phage was previously known to exhibit lytic activity broadly against all of the bacterial species and pathotypes listed in Table 4. This suggests that the isolated second phage exhibits broad lytic activity against Xanthomonas bacteria.

[0140] Like the first phage, the second phage is also likely to be applicable to various plant diseases, and these results suggest that it may be useful for controlling, for example, peach bacterial hole, walnut bacterial black spot, tomato bacterial spot, and lettuce bacterial spot, which are caused by bacteria of the genus Xanthomonas.

[0141] (5) Genome Analysis of the Second Phage The genomic DNA sequence of the second phage was determined and analyzed.

[0142] (i) Preparation and sequencing of the genomic DNA of the second phage TURBO DNA-free TMThe genome of the second phage was extracted using a PCR amplification kit (Thermo Fisher Scientific) according to the basic procedure described in "(5) Genome analysis of the first phage (i) Preparation and sequencing of genomic DNA of the first phage" in Example 1.

[0143] (ii) Bioinformatics Analysis Based on Genome Sequence Information Based on the genomic DNA sequence (SEQ ID NO: 2) of the second phage obtained in (i) above, a search for similar DNA sequences and confirmation of sequence identity was performed using the BLAST server provided by NCBI. The search results showed that the partial genomic DNA sequence of a phage targeting Xanthomonas bacteria, called Xp12 (access code: MT664984.1), had the highest similarity score, with 99.03% sequence identity over 99% of the full length of SEQ ID NO: 2. Based on these results, the sequence identity over the full length of SEQ ID NO: 2 is estimated to be approximately 98.04%. However, the only known bacterial species in which phage Xp12 exhibits bacteriolytic activity is Xanthomonas oryzae (Nakayinga R. et al., BMC Microbiology, 2021, 21:291).

[0144] Furthermore, while the total length of the Xp12 genomic DNA sequence is 63,783 bases, the total length of the genomic DNA sequence of the second phage isolated in this example was 35,321 bases, approximately half that length. Conversely, when the sequence identity based on the Xp12 genomic DNA sequence was calculated using GENETYX-NGS implemented in the genetic information processing software GENETYX (https: / / www.genetyx.co.jp / ), the base sequence of the second phage genomic DNA (SEQ ID NO: 2) had 98.34% sequence identity over 54% of the total length of the Xp12 genomic DNA sequence. From these results, the sequence identity when comparing the full-length genomic DNA sequences of both phages was estimated to be approximately 53.10%. Therefore, the genomic DNA sequence of the second phage obtained in this example only has a sequence homologous to a portion of the Xp12 genomic DNA sequence, and the overall similarity cannot be said to be high.

[0145] Further analysis of these differences in genomic DNA sequences was performed by comparing the genomic DNA sequences of Xp12 and the phage of the present invention using MUMmer, an implementation of the genetic information processing software GENETYX (https: / / www.genetyx.co.jp / ). As a result, no sequence homologous to the region from bases 12,894 to 41,320 of the Xp12 genomic DNA sequence was detected in the nucleotide sequence of SEQ ID NO: 2, indicating that this region was deleted in the genomic DNA sequence of the second phage. Based on their sequence identity, this region contained a gene (access code: QNN97189.1) that was presumed to be a tail fiber gene, a tail fiber gene (access code: QNN97196.1), and an endolysin gene (access code: QNN97201.1). These genes are deeply involved in the host infection process. This suggests that the second phage differs significantly in morphology and properties from Xp12, and that these differences contribute to the difference in host range. In addition to this, there were phages with base sequences that had relatively high similarity scores to the base sequence of sequence number 2, but all of them had a total length of over 60,000 bases, similar to the genomic DNA sequence of Xp12, and were phages with high similarity scores to the full length of the genomic DNA sequence of Xp12.

[0146] The search range was further expanded to include sequences with 80% or more sequence identity (identity) over 80% or more of the full length (query cover) of the genomic DNA sequence of the second phage. However, no known sequences with a high similarity score to the genomic DNA sequence of the second phage and a full length of 60,000 bases or less were detected on the BLAST server provided by NCBI.

[0147] These findings suggest that the second phage is a completely novel phage whose properties have been altered by the deletion of a portion of its genomic DNA.

[0148] Example 3: Isolation of a novel bacteriophage and its lytic activity (3) (Objective) A novel bacteriophage having lytic activity against pathogenic bacteria that cause plant diseases is isolated, and its lytic activity against plant pathogenic bacteria is verified.

[0149] (Methods and Results) (1) Obtaining and Cultivating Plant Pathogenic Bacteria In this example, the plant pathogenic bacteria were Xanthomonas bacteria, and all strains were obtained from the National Agriculture and Food Research Organization (NARO). Each bacterium used in this example is listed in Table 5 along with its NARO deposit number (MAFF No.).

[0150]

[0151] For control purposes, a strain of Pseudomonas fluorescens, a bacterium of the genus Pseudomonas, was obtained from NCIMB, a research institute within the UKNCC (NCIMB-ID: 10460).

[0152] Xanthomonas bacteria and Pseudomonas fluorescens were cultured according to the method described in Example 1, "(1) Obtaining and culturing plant pathogenic bacteria."

[0153] (2) Isolation and purification of the third phage The novel phage was isolated from natural wastewater or soil obtained in Japan. The isolation and purification methods were in accordance with the methods described in "(2) Isolation and purification of the first phage" in Example 1. As a result, one new phage was isolated from the natural wastewater and soil. This novel phage isolated in Example 3 is referred to as the "third phage."

[0154] The isolated phages were suspended in SM buffer and passed through a 0.2 μm filter to collect the phage-containing solution. This phage-containing solution was mixed with the bacterial solution under the above conditions, and the phages were isolated again. This procedure was repeated several times to purify the phages.

[0155] (3) Amplification and Purification of the Third Phage The plate lysate (PL) method was carried out to amplify and purify the isolated and purified third phage. The specific method was in accordance with the method described in "(3) Amplification and Purification of Phage" in Example 1. The titer of the prepared purified third phage solution was determined by plaque assay using an appropriately diluted solution, and the titer was 10 8 It was confirmed that the PFU / mL or more.

[0156] (4) Evaluation of host range of the third phage The host range of the third phage was evaluated by a spot test method. The basic procedure was in accordance with the method described in "(4) Evaluation of host range of the first phage" in Example 1.

[0157] An example of the results is shown in Figure 5. If the third phage exhibits lytic activity, only the area of ​​the bacterial lawn formed on the plate where the phage purified solution was dropped will become transparent. The third phage obtained by the present invention exhibited lytic activity against all of the Xanthomonas bacteria listed in Table 5. However, it did not exhibit lytic activity against Pseudomonas fluorescens. No phage was previously known to exhibit lytic activity broadly against all of the bacterial species and pathotypes listed in Table 5. This suggests that the isolated third phage exhibits broad lytic activity against Xanthomonas bacteria.

[0158] Furthermore, these results suggest that the third phage is useful for controlling diseases caused by Xanthomonas bacteria, such as walnut bacterial black spot, tomato bacterial spot, lettuce bacterial spot, and broccoli black rot.

[0159] (5) Genome Analysis of the Third Phage The genomic DNA sequence of the third phage was determined and analyzed.

[0160] (i) Preparation and sequencing of genomic DNA of the third phage TURBO DNA-free TM The genome of the third phage was extracted using a PCR amplification kit (Thermo Fisher Scientific) according to the basic procedure described in "(5) Genome analysis of the first phage (i) Preparation and sequencing of genomic DNA of the first phage" in Example 1.

[0161] (ii) Bioinformatics analysis based on genome sequence information Based on the base sequence (SEQ ID NO: 3) of the genome DNA of the third phage obtained in (i) above, a search for similar DNA sequences and confirmation of sequence identity was carried out using the BLAST server provided by NCBI. As a result of the search, the genome DNA sequence of a phage called vB_SmaS_P15 (access code: OK490494.1) that targets the genus Stenotrophomonas bacteria had the highest similarity score, with a sequence identity of 85.20% (Query Cover: SEQ ID NO: 3 had 96.82% sequence identity over 88% of its entire length. From this result, the sequence identity over the entire length is estimated to be approximately 85.20%. Similarly, the known phage with the second highest genomic DNA sequence identity (phage name: BUCT598, access code: MW831865.1, sequence identity over the entire length: approximately 85.18%) and the known phage with the third highest genomic DNA sequence identity (phage names: BUCT703 and BUCT700, access codes: OM735688.1 and OM735686.1, respectively, sequence identity over the entire length: approximately 56.7%) both targeted the genus Stenotrophomonas.

[0162] This result suggested that the third phage was a completely novel phage that uses Xanthomonas bacteria as a host.

[0163] Example 4: Lytic activity of the obtained bacteriophage combination (1) (Objective) Novel bacteriophages that have been shown to have lytic activity when used alone against pathogenic bacteria that cause plant diseases were examined for their effectiveness against plant diseases when used in combination.

[0164] (Methods) (1) Spot test method A spot test was carried out according to the method described in "(4) Evaluation of host range of first phage" in Example 1. In this example, Xanthomonas cucurbitae (MAFF No. 673005) and Xanthomonas campestris pv. vitians (MAFF No. 301352), strains for which the bacteriolytic activity of all tested phages has been confirmed, were used.

[0165] The phage purified solution to be dropped was a mixed solution prepared by mixing equal amounts of the phage purified solutions prepared in each Example. The mixed solution was prepared by diluting appropriately so that the total titer was equivalent to that when each phage was used alone. The phages used in this Example are as follows.

[0166] In this example, a first phage having the genomic DNA sequence of SEQ ID NO: 1 (a in Figure 6B) was used in combination with a phage having the genomic DNA sequence of SEQ ID NO: 4 (b in Figure 6B), a phage having the genomic DNA sequence of SEQ ID NO: 5 (c in Figure 6B), a phage having the genomic DNA sequence of SEQ ID NO: 6 (d in Figure 6B), a phage having the genomic DNA sequence of SEQ ID NO: 7 (e in Figure 6B), a second phage having the genomic DNA sequence of SEQ ID NO: 2 (f in Figure 6B), a third phage having the genomic DNA sequence of SEQ ID NO: 3 (g in Figure 6B), and a phage having the genomic DNA sequence of SEQ ID NO: 8 (h in Figure 6B).

[0167] (Results) An example of the results is shown in Figure 6. When a phage combination exhibits bacteriolytic activity, only the area of ​​the bacterial lawn formed on the plate where the phage purified solution was dropped becomes transparent. It was found that both of the two tested combinations exhibited bacteriolytic activity at least as good as when each phage was used alone (Figure 6).

[0168] From the above results, it was confirmed that the phages of the present invention are useful whether used alone or in combination.

[0169] Example 5: Lytic activity of the obtained bacteriophage combination (2) (Objective) Novel bacteriophages that have been shown to have lytic activity when used alone against pathogenic bacteria that cause plant diseases were examined for their effectiveness against plant diseases when used in combination.

[0170] (Methods) (1) Spot test method A spot test was carried out according to the method described in "(4) Evaluation of host range of first phage" in Example 1. In this example, Xanthomonas cucurbitae (MAFF No. 673005) and Xanthomonas campestris pv. vitians (MAFF No. 301352), strains for which the bacteriolytic activity of all tested phages has been confirmed, were used.

[0171] The phage purified solution to be dropped was a mixed solution prepared by mixing equal amounts of the phage purified solutions prepared in each Example. The mixed solution was prepared by diluting appropriately so that the total titer was equivalent to that when each phage was used alone. The phages used in this Example are as follows.

[0172] In this example, a second phage having the genomic DNA sequence of SEQ ID NO: 2 (a in Figure 7B) was used in combination with a phage having the genomic DNA sequence of SEQ ID NO: 4 (b in Figure 7B), a phage having the genomic DNA sequence of SEQ ID NO: 5 (c in Figure 7B), a phage having the genomic DNA sequence of SEQ ID NO: 6 (d in Figure 7B), a phage having the genomic DNA sequence of SEQ ID NO: 7 (e in Figure 7B), a first phage having the genomic DNA sequence of SEQ ID NO: 1 (f in Figure 7B), a third phage having the genomic DNA sequence of SEQ ID NO: 3 (g in Figure 7B), and a phage having the genomic DNA sequence of SEQ ID NO: 8 (h in Figure 7B).

[0173] (Results) An example of the results is shown in Figure 7. When a phage combination exhibits lytic activity, only the area of ​​the bacterial lawn formed on the plate where the phage purified solution was dropped becomes transparent. It was found that both of the two tested combinations exhibited lytic activity at least as good as when each phage was used alone (Figure 7).

[0174] From the above results, it was confirmed that the phages of the present invention are useful whether used alone or in combination.

[0175] Example 6: Lytic activity of the obtained bacteriophage combination (3) (Objective) Novel bacteriophages that have been shown to have lytic activity when used alone against pathogenic bacteria that cause plant diseases were examined for their effectiveness against plant diseases when used in combination.

[0176] (Methods) (1) Spot test method A spot test was performed according to the method described in "(4) Evaluation of host range of first phage" in Example 1. In this example, the strains used were Xanthomonas cucurbitae (MAFF No. 673005), Xanthomonas campestris pv. vesicatoria (MAFF No. 301257), and Xanthomonas campestris pv. campestris (MAFF No. 106765), which had been confirmed to have lytic activity for all tested phages.

[0177] The phage purified solution to be dropped was a mixed solution prepared by mixing equal amounts of the phage purified solutions prepared in each Example. The mixed solution was prepared by diluting appropriately so that the total titer was equivalent to that when each phage was used alone. The phages used in this Example are as follows.

[0178] In this example, a third phage having the genomic DNA sequence of SEQ ID NO: 3 (a in Figure 8B) was used in combination with a phage having the genomic DNA sequence of SEQ ID NO: 4 (b in Figure 8B), a phage having the genomic DNA sequence of SEQ ID NO: 5 (c in Figure 8B), a phage having the genomic DNA sequence of SEQ ID NO: 6 (d in Figure 8B), a phage having the genomic DNA sequence of SEQ ID NO: 7 (e in Figure 8B), a first phage having the genomic DNA sequence of SEQ ID NO: 1 (f in Figure 8B), a second phage having the genomic DNA sequence of SEQ ID NO: 2 (g in Figure 8B), and a phage having the genomic DNA sequence of SEQ ID NO: 8 (h in Figure 8B).

[0179] (Results) An example of the results is shown in Figure 8. When a phage combination exhibits bacteriolytic activity, only the area of ​​the bacterial lawn formed on the plate where the phage purified solution was dropped becomes transparent. It was found that both of the two tested combinations exhibited bacteriolytic activity at least as good as when each phage was used alone (Figure 8).

[0180] From the above results, it was confirmed that the phages of the present invention are useful whether used alone or in combination.

[0181] Example 7: Test of disease control effect against bacterial spot of tomato (Objective) The effect of isolated novel bacteriophages having lytic activity against pathogenic bacteria of plant diseases on plant diseases when applied to plants was examined.

[0182] (Method) (1) Preparation of phage spray solution The phage spray solution used in this test was prepared as follows. First, a culture solution of the host bacteria for phage amplification was prepared as follows. The host used was Xanthomonas campestris pv. vesicatoria (MAFF No. 301256), a strain in which lytic activity has been confirmed for all tested phages. The bacterial cells were inoculated into YPG broth and incubated overnight in a shaker set at 25°C. After incubation, the OD 600 The turbidity (at a wavelength of 600 nm) was measured, and the one that reached about 1.0 was used as the bacterial culture solution below.

[0183] The prepared bacterial cell culture solution and the purified phage solution containing one type of phage prepared in Example 1 (titer 10 8 A mixture of equal amounts of phage (approximately PFU / mL) was inoculated into 100 times the volume of YPG culture medium and incubated for approximately 8-12 hours in a shaker set at 25°C. The resulting culture medium was recovered as a crude phage solution. One-tenth the volume of chloroform was added to the recovered crude solution, and after vigorously stirring, the solution was centrifuged at 8,000g / 20°C / 5 minutes to recover the supernatant. The recovered supernatant was passed through a 0.2 μm filter, and the filtrate was used as a purified phage solution.

[0184] As a phage dispersion solution containing one type of phage, the purified phage solution was used to obtain a titer of approximately 10 9 The solution was diluted with sterile tap water to a concentration of approximately PFU / mL.

[0185] (2) Preparation of bacterial spray solution The bacterial spray solution used for infecting plants in this test was prepared using the bacterial culture solution prepared in (1). The bacterial culture solution was diluted approximately 10,000 times with sterile tap water and applied to a YPG agar plate, which was then incubated in an incubator set at 25°C for approximately 1 to 3 days. The bacterial suspension was collected by suspending colonies on the YPG agar plate in sterile tap water, and the final OD 600 The solution was diluted with sterilized tap water to a concentration of about 0.5 to prepare a bacterial spray solution.

[0186] (3) Plant Samples Commercially available tomato seeds were sown and grown in a greenhouse. Seedlings with 50 or more leaves were used as samples for evaluation.

[0187] (4) Phage application and infection treatment. In the phage treatment group, each specimen was foliar-sprayed with the phage solution twice, twice before and twice after bacterial infection, with an interval of 2–3 days between each treatment. Two to three days later, the infected specimens were sprayed with the bacterial solution. The infected specimens were left in a greenhouse with high humidity for approximately two days after infection. Then, the phage solution was sprayed twice more on the leaves, with an interval of 2–3 days between each treatment. The untreated group was treated in the same manner as above, except that sterilized tap water was used instead of the purified phage solution.

[0188] (5) Measurement of Disease Incidence Sixteen days after infection, the disease incidence was investigated in the untreated group and each phage-sprayed group.

[0189] Leaves showing the characteristics of bacterial spot disease on the surface of tomato were considered to be diseased, and the ratio of the number of diseased leaves to the total number of leaves was calculated as the disease incidence rate. The relative disease incidence rate in the phage-treated group was calculated as a relative value when the disease incidence rate in the untreated group was set at 100%.

[0190] (Results) The results are shown in Figure 9. The disease incidence rate in the untreated group was approximately 25%. On the other hand, the relative disease incidence rate, with the disease incidence rate in the untreated group taken as 100%, was approximately 51.1% when the phage spray solution containing the first phage was applied.

[0191] From the above, it was found that the phages of the present invention can effectively protect plants from diseases even when applied to actual plants.

[0192] In the phage-treated group, no noticeable adverse effects on the plants that are thought to be caused by the phages, such as phytotoxicity on the leaves, were observed. This demonstrates that application of the phages of the present invention is an effective means of disease control with few side effects.

[0193] Example 8: Test of disease control effect against black rot of broccoli (Objective) The effect of isolated novel bacteriophages having lytic activity against pathogenic bacteria of plant diseases on plant disease when applied to plants was examined.

[0194] (Method) (1) Preparation of phage spray solution A phage spray solution was prepared in accordance with the description of Example 7, except that the bacterium used as the bacterial cell was Xanthomonas campestris pv. campestris (MAFF No. 106765) and the following phages were used.

[0195] The phage dispersion solution containing multiple types of phages was prepared by mixing equal amounts of purified phage solutions adjusted to have the same titer. 9 The solution was diluted with sterile tap water to a concentration of approximately PFU / mL.

[0196] In this example, a third phage having the genomic DNA sequence of SEQ ID NO: 3 (a in Figure 10) was used in combination with a phage having the genomic DNA sequence of SEQ ID NO: 9 (b in Figure 10), or additionally with a phage having the genomic DNA sequence of SEQ ID NO: 8 (c in Figure 10) and a phage having the genomic DNA sequence of SEQ ID NO: 10 (d in Figure 10), or additionally with a phage having the genomic DNA sequence of SEQ ID NO: 5 (e in Figure 10) and a phage having the genomic DNA sequence of SEQ ID NO: 6 (f in Figure 10), in combination with a phage having the genomic DNA sequence of SEQ ID NO: 7 (g in Figure 10) and a phage having the genomic DNA sequence of SEQ ID NO: 11 (h in Figure 10).

[0197] (2) Preparation of bacterial spray solution A phage spray solution was prepared in accordance with the description of Example 7, except that the bacterial cells were the above-mentioned bacteria.

[0198] (3) Plant Samples Commercially available broccoli seeds were sown and grown in a greenhouse. Seedlings with five or more leaves were used as samples for evaluation.

[0199] (4) Phage application and infection treatment were carried out in accordance with the description in Example 7.

[0200] (5) Measurement of Disease Incidence The same procedure as in Example 7 was followed, except that the evaluation was carried out 16 days after infection.

[0201] (Results) The results are shown in Figure 10. The disease incidence in the untreated group was approximately 52%. On the other hand, the relative disease incidence, with the disease incidence in the untreated group taken as 100%, was approximately 56% when the phage spray solution containing only the third phage was applied ("a" in Figure 10).

[0202] Furthermore, when a phage spray containing two or more phages was applied, the relative incidence rate further decreased to an average of approximately 45.7%. Although the relative incidence rate was approximately 60% when a third phage and one other phage were combined (for a total of two phages) ("a / b" in Figure 10), the tendency was generally observed that the more phage types combined, the higher the disease control effect and the lower the relative incidence rate. Specifically, when a total of four phages were combined, the relative incidence rate was approximately 43.5% ("a / b / c / d" in Figure 10), and when a total of eight phages were combined, the relative incidence rate was approximately 33.5% ("a / b / c / d / e / f / g / h" in Figure 10).

[0203] From the above, it was found that the phages of the present invention can effectively control plants from diseases, regardless of the type of plant itself, even when applied to actual plants. It was also found that a higher effect can be obtained by applying the phages of the present invention in combination.

[0204] In the phage-treated group, no noticeable adverse effects on the plants that could be attributed to the phages, such as phytotoxicity to the leaves, were observed. This demonstrates that application of the phages of the present invention is an effective means of disease control with few side effects. All publications, patents, and patent applications cited herein are incorporated herein by reference in their entirety.

Claims

1. A lytic agent comprising a bacteriophage having a genomic DNA sequence consisting of the base sequence shown in any one of SEQ ID NOs: 3, 1 or 2.

2. The lytic agent according to claim 1, which exhibits lytic activity against Xanthomonas bacteria.

3. A composition comprising the lytic agent according to claim 1 or 2 as an active ingredient.

4. A plant disease control composition comprising the composition according to claim 3.

5. The plant disease control composition according to claim 4, wherein the plant disease is caused by a bacterium of the genus Xanthomonas.

6. The plant disease control composition according to claim 4, which contains another bacteriophage exhibiting lytic activity against Xanthomonas bacteria.

7. A method for controlling plant diseases, comprising a contacting step of contacting a target plant with the plant disease control composition according to claim 4.

8. A method for identifying Xanthomonas bacteria, comprising: a culturing step of culturing a test bacterium isolated from plant tissue infected with a plant disease to obtain a culture; a mixing step of mixing the culture with the lytic agent described in claim 2 to obtain a mixture; a mixture culturing step of culturing the mixture under specified conditions; and a determination step of determining that the test bacterium is a Xanthomonas bacterium if the test bacterium has been lysed after the mixture culturing step.

9. The method of claim 8, wherein in said mixture culturing step, said mixture further comprises a soft agar-containing liquid medium, and the mixture is cultured on a solid medium.

10. The method of claim 8, wherein in the culturing step, the culture comprises a soft agar-containing liquid medium and the culture is cultivated on a solid medium.

11. The method of claim 8, further comprising an isolation step of isolating the test bacterium from plant tissue affected by a plant disease prior to said culturing step.

Citation Information

Patent Citations

  • Methods and compositions for treating and controlling plant diseases

    JP2015534983A

  • Bacteriophage, detection agent for citrus xanthomonas axonopodis, detection method for citrus xanthomonas axonopodis, control agent of xanthomonas campestris, and control method of xanthomonas campestris

    JP2016032435A